Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

Ionis’ investigational antisense therapy shows promise in Angelman syndrome

ION582 is expected to enter late-stage development for the rare neurodevelopmental disorder in 2025

- PMLiVE

WHO calls for better medicines access to close neurological disorders treatment gap

In 2021, neurological conditions affected more than three billion people worldwide

- PMLiVE

ICR study on cell competition mechanism could lead to new ways of treating cancer

Female breast, lung, bowel and prostate cancers account for more than four in ten of all cancers worldwide

- PMLiVE

Enhancing participant payments: a new approach with IQVIA’s Participant Payments solution

IQVIA has developed a solution designed to simplify and streamline the payment process for all stakeholders involved in clinical trials

- PMLiVE

Unlocking access to CAR-T in Europe: progress and growing pains

CAR-Ts pose a unique challenge for healthcare systems, exacerbated by uncertainty around their long-term, real-world value

- PMLiVE

Top 10 Medical Education Trends of 2024

Discover the top 10 trends revolutionizing medical education, from VR and gamification to microlearning and AI, making learning more personalized, interactive, and effective. Read the full article to explore how...

Impetus Digital

- PMLiVE

Novo Nordisk’s semaglutide approved by MHRA to prevent cardiovascular event risk

Approximately 7.6 million people are living with heart and circulatory diseases in the UK

- PMLiVE

NHS figures reveal record number of people in England being diagnosed with dementia

Around a third of people living with dementia in England have not received a diagnosis

- PMLiVE

Merck’s investigational RSV monoclonal antibody clesrovimab shown to protect infants

The respiratory virus accounts for about 30,000 hospitalisations in children under five every year in the UK

- PMLiVE

GSK’s ViiV shares positive head-to-head results for two-drug HIV regimen Dovato

The phase 4 trial has been comparing Dovato against Gilead’s three-drug regimen, Biktarvy

- PMLiVE

Researchers develop AI model to identify breast cancer stages and progression

Up to 50% of ductal carcinoma in situ patients progress to a highly invasive stage of cancer

- PMLiVE

How good are you at filtering fact from fiction?

By Vicky Bramham

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links